Evidence map›Paper›PMID 38632187›Full record

ArticlePharmacological reports : PR2024

Partial mGlu

Agnieszka Pałucha-Poniewiera, Anna Rafało-Ulińska, Michal Santocki, Yana Babii, Katarzyna Kaczorowska

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmacological reports : PR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. (R)-ketamine induces mGluPsychopharmacology · 2025
    Article
  3. Spontaneous glutamate release activates mGluR signaling to drive rapid antidepressant responses.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Article
  5. Article
  6. (International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Agnieszka Pałucha-PoniewieraDepartment of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków, 31-343, Poland. nfpaluch@cyf-kr.edu.pl.ORCID http://orcid.org/0000-0001-9890-6844
Anna Rafało-UlińskaDepartment of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków, 31-343, Poland.
Michal SantockiDepartment of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków, 31-343, Poland.
Yana BabiiDepartment of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków, 31-343, Poland.
Katarzyna KaczorowskaDepartment of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków, 31-343, Poland.
Maj Institute of Pharmacology · PL

Funding

Narodowe Centrum Nauki 2017/27/B/NZ7/01873
6 · The paper itself

Abstract

backgroundPartial negative allosteric modulators (NAM) of the metabotropic glutamate 5 (mGlu

methodsA tail suspension test (TST) was used to investigate acute antidepressant-like effects. Sustained effects were studied 24 h after the four intraperitoneal (ip) administrations using the splash test, designed to measure apathy-like state, the sucrose preference test (SPT), reflecting anhedonia, and the TST. Western blot and ELISA techniques were used to measure brain-derived neurotrophic factor (BDNF) and selected protein levels.

methodsA tail suspension test (TST) was used to investigate acute antidepressant-like effects. Sustained effects were studied 24 h after the four intraperitoneal (ip) administrations using the splash test, designed to measure apathy-like state, the sucrose preference test (SPT), reflecting anhedonia, and the TST. Western blot and ELISA techniques were used to measure brain-derived neurotrophic factor (BDNF) and selected protein levels.

conclusionPartial mGlu

Indexed as

Antidepressive AgentsBrain-Derived Neurotrophic FactorHindlimb SuspensionKetaminePyridinesReceptor, Metabotropic Glutamate 5AlkynesAllosteric RegulationAnhedoniaAnimalsBehavior, AnimalDepressionDisease Models, AnimalMaleMice2-(2-(3-methoxyphenyl)ethynyl)-5-methylpyridineAlkynesAntidepressive AgentsBdnf protein, mouseBrain-Derived Neurotrophic FactorKetaminePyridinesReceptor, Metabotropic Glutamate 5AntidepressantBDNFM-5MPEPmGlu5 receptorRAAD(R)-ketamineTrkB receptor

Identifiers

PMID38632187
OpenAlexW4394921488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.